Member Info for RayPointer

Thanks invest
Interesting read.
But what specifically makes you think that now is the time to invest?

Nice to see a good pump and dump is alive and kicking

Karolinska Development AB is just across the road from the institut

https://www.karolinskadevelopment.com/index.php/en/contact-us

and their 2 analysts are both graduates from the institut

https://www.karolinskadevelopment.com/index.php/en/our-people

Looks like they are allowed to wear jeans to work. My kind of company.

So perhaps Karolinska development AB are keeping an eye on the Scancell/Karolinska institut collaboration.

Another reason for recruiting Sam as this collaboration may move towards trials/commercialisation via the links between the institut and the development AB.

Only supposition at present.

From a Merck point of view, I would imagine it is about keeping the Keytruda juggernaut going and perhaps even increasing momentum.

But what it also shows is that Merck is willing to shell out on a positive combo trial.

http://www.immunedesign.com/wp-content/uploads/2018/11/ASH-2018-G-and-P-Poster-FINAL.pdf

The company is being bought by Merck, presumably on the results of their combo trial GP100 (their lead product) and Keytruda.
See table 5. This perhaps sets the benchmark for the SCIB1/Keytruda trial.

Ruck

I hope so. Our last effort at getting inside information ended with TCell eating our mole.

Tomorrow they're changing their cleaners.
Can't wait Lol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706602/

I feel sure that this has been posted previously.
I am re-posting since it is very relevant to Immunobody.
In fact there is quite a long paragraph on SCIB1.

Final sentence of concluding remarks

" Novel combinatorial approaches that unleash the full clinical potential of DNA-based vaccines are urgently awaited."

Come on FDA, our SCIB1 combo trial is urgently awaited.

bank to bank transactions about to take off?

I agree kezzman

To me, the important points in the RNS are:

"In December 2018, approximately 32% of gross value flows across the HomeSend platform were generated from account-to-account transactions."

"As at the end of December 2018, HomeSend had approximately 50 implementation projects ongoing with a combination of both send and receive banking partners."

Yes, who knows. It is hard to predict price movements on Aim
But 6.8 is a definite recent support level.

IMO, looks like the SP may retrace back to around 6.8, so this level looks like it could be a good price to buy more

My best wishes to you C7.
It sounds like a long day for you.
Great match in prospect tonight though, something to look forward to.

So the challenge is to find a vaccine, other than Moditope, that generates high avidity CD4 killer cells.

I tried but I couldn't find one.
There are articles about using CD4 as helper cells with CD8 being the killers (i.e. like Immunobody).
Maybe some companies are working on CD4 killer cells and keeping quiet.

And the a Nobel Prize winner comes out and says
“I think there are ways around that, involving the development of CD4-TARGETED AGENTS, particularly using VACCINES” .'

So, as far as we know, Moditope looks like it has a unique recipe

The ingredients being

the activation of CD4 killer cells
2 classes of targets discovered (citrullinated and homocitrullinated)
The possibility of more classes of targets
High avidity
Clonal expansion
Low TCell infiltration of the tumour
A chain reaction that induces more stress on the tumour and hence more expression of the target
No serious side effects
A memory effect

This is all in humanised mice at present but experiments have also been performed on human blood.
And then we have the BionTech collaboration on-going and expanded to include Modi2.

So, if the mice results are replicated in humans........

it's the medical equivalent of a nuclear explosion IMO (and coincidentally it also has its own chain reaction)

“You cannot cure cancer by a majority. What is needed is a remedy.”

The other aspect of Ruhul's appointment is Lindy as a talent spotter as crumbs has alluded to in the past.
Does Lindy have a team of talent scouts at other Unis LOL?

Ruhul looks like a good addition to the team

"He recently completed his PhD at the University of Manchester where he led a research project to elucidate the mechanisms of uterine decidual spiral artery remodelling,"

Not an oncologist then, but he led a research project as a PHD student. How often do you see this?

"At Scancell his key responsibility is designing new peptide vaccines that could potentially induce the immune response and kill tumours in mice."

"new peptide vaccines"
New Moditope vaccines without a doubt.
But could he also be involved in the Mass Spectrometry work sponsored by Scancell at Durham Uni and Liverpool Uni?
So he may also be involved in the search for new siPTMs. (stress induced post-translational modifications)

Looks very much like another strengthening of the research team. Another confident move?

Do I see a buy for 7p?